Crossover invests in establishing and staffing the CRUs that are responsible for conducting all clinical trials carried out at the selected healthcare institutions which are part of the Crossover network. Over the next 10 years, it is expected that this network will expand to include more than 175 healthcare institutions in all parts of the world.
In parallel, Crossover establishes access to the hospital information systems (HIS) of healthcare institutions within the network, populating on a continuous basis the Epidemiology Database (EPIDAB) and warehousing de-identified electronic medical record/electronic health record patient data.
Crossover improves the feasibility of clinical trials and provides population studies of better quality and at a more affordable cost than healthcare institutions without a dedicated CRU. Its epidemiology database (EPIDAB) is used for data mining to support a wide range of medical, scientific and market research needs (interventional and non-interventional clinical trials, non-applied clinical research and market research) of significant interest to pharmaceutical companies, academic researchers, CROs and healthcare planners, providers and insurers.
- Lower costs through proximity with medical technology clusters and the use of academic and healthcare institution staff peripherally on an ad hoc basis rather than central staff
- Closer cooperation with sponsors through the distribution of project managers at healthcare institutions in close vicinity of sponsor clusters
- Bridging the gap between healthcare databases and clinical trial databases through the standardisation of work practice and use of internationally recognised coding systems and nomenclature, the continuous development of sophisticated data collection and validation systems in healthcare practice and clinical research, intensive training of staff at research sites and the use of advanced integrated IT systems
- Objective feasibility studies, faster project turnaround and higher quality


